Vascular Endothelial Growth Factor (VEGF) Inhibitors Market to grow at a CAGR of 7.76% from 2022 to 2027; Driven by the strategic alliances formed regarding collaboration and licensing - Technavio

NEW YORK, June 21, 2023 /PRNewswire/ -- The global vascular endothelial growth factor (VEGF) inhibitors market size is estimated to grow by USD 10,400.61 million from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 7.76% during the forecast period. The strategic alliances formed for collaboration and licensing are driving the market growth significantly during the forecast period. Alliances help to co-develop and commercialize VEGF inhibitors worldwide. Co-development agreements bring in technical expertise from both organizations, which helps them promote, develop and market novel drugs. Such collaborations also ensure the in-flow of substantial funds for the organizations involved and reduce liability costs incurred by individual companies in case of failures. This results in attracting more venture investments. Thus, strategic alliances are expected to propel the growth of the VEGF inhibitors market during the forecast period.

For more insights on the historic market data (2017 to 2021) and forecast market size
(2023 to 2027) - Request a sample report

What's New?

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession 
• Global competitiveness and key competitor positions 
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial  - buy the report!

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market - Segmentation Assessment
Segment Overview
Technavio has segmented the market based on application (oncology and ophthalmology), type (VEGF-A inhibitor, VEGF-B inhibitor, VEGF-C inhibitor, and VEGF-D inhibitor), and geography (North America, Europe, Asia, and Rest Of World (ROW)).

• The market share growth of the oncology segment will be significant for the growth of the global vascular endothelial growth factor (VEGF) inhibitors market during the forecast period. The commonly used VEGF inhibitors in the oncology segment include bevacizumab (Avastin), aflibercept (Zaltrap), and ramucirumab (Cyramza). The rapid growth of the segment can be attributed to factors such as the increasing incidence of cancer, the availability of new drugs, and the high demand for effective cancer treatments, which, in turn, contribute to the growth of the global VEGF inhibitors market during the forecast period.

Geography Overview
By geography, the global vascular endothelial growth factor (VEGF) inhibitors market is segmented into North America, Europe, Asia, and the Rest of the World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global vascular endothelial growth factor (VEGF) inhibitors market.

• North America is estimated to contribute 44% to the growth of the global vascular endothelial growth factor (VEGF) inhibitors market during the forecast period. The sales of approved VEGF inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC primarily drive the growth of the market in this region.

Insights on the market contribution of various segments including country and region
wise, historic market data (2017 to 2021), and forecast market size (2023 to 2027) -
Download a Sample Report

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market – Market Dynamics

Leading trends influencing the market 

The growing popularity of combination therapies is one of the major trends in the market. According to research by pharmaceutical companies, some metastatic cancer does not respond to a monotherapy drug. Drugs given to treat cancer are most effective when given in combination. Hence, the rise in the use of a combination of chemotherapies to treat cancer as well as ophthalmic conditions, which will have a positive impact on the VEGF inhibitors market during the forecast period.

Major challenges hindering the market growth

Preference for gene therapy is a prominent challenge that may impede market growth during the forecast period. Recent research developments in oncology and ophthalmology, have discovered that several carcinomas and eye disorders are caused due to abnormal gene mutations, which occur from the damage to genes in a cell during a person's life span. The minimum side effects and the remissive nature of this therapy make this a popular treatment option. Hence, the growing preference for gene therapy will hamper the growth of the global VEGF inhibitors market during the forecast period.

Insights on market drivers, trends, & challenges, historic period(2017 to 2021), and
forecast period(2023 to 2027)- Request a sample report!

What are the key data covered in this Vascular Endothelial Growth Factor (VEGF) Inhibitors Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the vascular endothelial growth factor (VEGF) inhibitors market between 2023 and 2027
• Precise estimation of the size of the vascular endothelial growth factor (VEGF) inhibitors market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the vascular endothelial growth factor (VEGF) inhibitors market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of vascular endothelial growth factor (VEGF) inhibitors market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The beta lactam and beta lactamase inhibitors market size is expected to increase to USD 9.04 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. A major factor driving growth in the beta lactam and beta lactamase inhibitors market is the special regulatory designations.

The PD-1 and PD-L1 inhibitors market size is expected to increase by USD 49.34 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 19.31%. A key factor driving growth in the PD-1 and PD-L1 inhibitors market is the increasing prevalence of cancer.

Table of Contents 

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global vascular endothelial growth factor (VEGF) inhibitors market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global vascular endothelial growth factor (VEGF) inhibitors market 2017 - 2021 ($ million)

• 4.2 Application Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ million)

• 4.3 Type Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Application

• 6.1 Market segments 
• Exhibit 30: Chart on Application - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Application - Market share 2022-2027 (%)

• 6.2 Comparison by Application 
• Exhibit 32: Chart on Comparison by Application
• Exhibit 33: Data Table on Comparison by Application

• 6.3 Oncology - Market size and forecast 2022-2027
• Exhibit 34: Chart on Oncology - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oncology - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oncology - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oncology - Year-over-year growth 2022-2027 (%)

• 6.4 Ophthalmology - Market size and forecast 2022-2027
• Exhibit 38: Chart on Ophthalmology - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Ophthalmology - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Ophthalmology - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Ophthalmology - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Application 
• Exhibit 42: Market opportunity by Application ($ million)

7 Market Segmentation by Type

• 7.1 Market segments 
• Exhibit 43: Chart on Type - Market share 2022-2027 (%)
• Exhibit 44: Data Table on Type - Market share 2022-2027 (%)

• 7.2 Comparison by Type 
• Exhibit 45: Chart on Comparison by Type
• Exhibit 46: Data Table on Comparison by Type

• 7.3 VEGF-A inhibitor - Market size and forecast 2022-2027
• Exhibit 47: Chart on VEGF-A inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Data Table on VEGF-A inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Chart on VEGF-A inhibitor - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on VEGF-A inhibitor - Year-over-year growth 2022-2027 (%)

• 7.4 VEGF-B inhibitor - Market size and forecast 2022-2027
• Exhibit 51: Chart on VEGF-B inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on VEGF-B inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on VEGF-B inhibitor - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on VEGF-B inhibitor - Year-over-year growth 2022-2027 (%)

• 7.5 VEGF-C inhibitor - Market size and forecast 2022-2027
• Exhibit 55: Chart on VEGF-C inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on VEGF-C inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on VEGF-C inhibitor - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on VEGF-C inhibitor - Year-over-year growth 2022-2027 (%)

• 7.6 VEGF-D inhibitor - Market size and forecast 2022-2027
• Exhibit 59: Chart on VEGF-D inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on VEGF-D inhibitor - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on VEGF-D inhibitor - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on VEGF-D inhibitor - Year-over-year growth 2022-2027 (%)

• 7.7 Market opportunity by Type 
• Exhibit 63: Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 65: Chart on Market share by geography 2022-2027 (%)
• Exhibit 66: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 67: Chart on Geographic comparison
• Exhibit 68: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Canada - Market size and forecast 2022-2027
• Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 Germany - Market size and forecast 2022-2027
• Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.11 Japan - Market size and forecast 2022-2027
• Exhibit 101: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 105: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 106: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 107: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 108: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 109: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 110: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 111: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 112: AbbVie Inc. - Overview
• Exhibit 113: AbbVie Inc. - Product / Service
• Exhibit 114: AbbVie Inc. - Key news
• Exhibit 115: AbbVie Inc. - Key offerings

• 12.4 Amgen Inc. 
• Exhibit 116: Amgen Inc. - Overview
• Exhibit 117: Amgen Inc. - Product / Service
• Exhibit 118: Amgen Inc. - Key offerings

• 12.5 AstraZeneca Plc 
• Exhibit 119: AstraZeneca Plc - Overview
• Exhibit 120: AstraZeneca Plc - Product / Service
• Exhibit 121: AstraZeneca Plc - Key news
• Exhibit 122: AstraZeneca Plc - Key offerings

• 12.6 Bausch Health Co Inc. 
• Exhibit 123: Bausch Health Co Inc. - Overview
• Exhibit 124: Bausch Health Co Inc. - Business segments
• Exhibit 125: Bausch Health Co Inc. - Key news
• Exhibit 126: Bausch Health Co Inc. - Key offerings
• Exhibit 127: Bausch Health Co Inc. - Segment focus

• 12.7 Bayer AG 
• Exhibit 128: Bayer AG - Overview
• Exhibit 129: Bayer AG - Business segments
• Exhibit 130: Bayer AG - Key news
• Exhibit 131: Bayer AG - Key offerings
• Exhibit 132: Bayer AG - Segment focus

• 12.8 Bristol Myers Squibb Co. 
• Exhibit 133: Bristol Myers Squibb Co. - Overview
• Exhibit 134: Bristol Myers Squibb Co. - Product / Service
• Exhibit 135: Bristol Myers Squibb Co. - Key news
• Exhibit 136: Bristol Myers Squibb Co. - Key offerings

• 12.9 Eisai Co. Ltd. 
• Exhibit 137: Eisai Co. Ltd. - Overview
• Exhibit 138: Eisai Co. Ltd. - Business segments
• Exhibit 139: Eisai Co. Ltd. - Key news
• Exhibit 140: Eisai Co. Ltd. - Key offerings
• Exhibit 141: Eisai Co. Ltd. - Segment focus

• 12.10 Eli Lilly and Co. 
• Exhibit 142: Eli Lilly and Co. - Overview
• Exhibit 143: Eli Lilly and Co. - Product / Service
• Exhibit 144: Eli Lilly and Co. - Key offerings

• 12.11 F. Hoffmann La Roche Ltd. 
• Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus

• 12.12 Merck and Co. Inc. 
• Exhibit 150: Merck and Co. Inc. - Overview
• Exhibit 151: Merck and Co. Inc. - Business segments
• Exhibit 152: Merck and Co. Inc. - Key news
• Exhibit 153: Merck and Co. Inc. - Key offerings
• Exhibit 154: Merck and Co. Inc. - Segment focus

• 12.13 Novartis AG 
• Exhibit 155: Novartis AG - Overview
• Exhibit 156: Novartis AG - Business segments
• Exhibit 157: Novartis AG - Key offerings
• Exhibit 158: Novartis AG - Segment focus

• 12.14 Pfizer Inc. 
• Exhibit 159: Pfizer Inc. - Overview
• Exhibit 160: Pfizer Inc. - Product / Service
• Exhibit 161: Pfizer Inc. - Key news
• Exhibit 162: Pfizer Inc. - Key offerings

• 12.15 Regeneron Pharmaceuticals Inc. 
• Exhibit 163: Regeneron Pharmaceuticals Inc. - Overview
• Exhibit 164: Regeneron Pharmaceuticals Inc. - Product / Service
• Exhibit 165: Regeneron Pharmaceuticals Inc. - Key offerings

• 12.16 Sanofi SA 
• Exhibit 166: Sanofi SA - Overview
• Exhibit 167: Sanofi SA - Business segments
• Exhibit 168: Sanofi SA - Key news
• Exhibit 169: Sanofi SA - Key offerings
• Exhibit 170: Sanofi SA - Segment focus

• 12.17 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 171: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist
• Exhibit 175: Inclusions checklist
• Exhibit 176: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 177: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 178: Research methodology
• Exhibit 179: Validation techniques employed for market sizing
• Exhibit 180: Information sources

• 13.5 List of abbreviations 
• Exhibit 181: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio